GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Amcad Biomed Corp (ROCO:4188) » Definitions » Return-on-Tangible-Asset

Amcad Biomed (ROCO:4188) Return-on-Tangible-Asset : -14.62% (As of Mar. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Amcad Biomed Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Amcad Biomed's annualized Net Income for the quarter that ended in Mar. 2024 was NT$-62.56 Mil. Amcad Biomed's average total tangible assets for the quarter that ended in Mar. 2024 was NT$427.96 Mil. Therefore, Amcad Biomed's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2024 was -14.62%.

The historical rank and industry rank for Amcad Biomed's Return-on-Tangible-Asset or its related term are showing as below:

ROCO:4188' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -24.24   Med: -9.34   Max: -4.71
Current: -11.42

During the past 13 years, Amcad Biomed's highest Return-on-Tangible-Asset was -4.71%. The lowest was -24.24%. And the median was -9.34%.

ROCO:4188's Return-on-Tangible-Asset is ranked worse than
58.2% of 866 companies
in the Medical Devices & Instruments industry
Industry Median: -2.715 vs ROCO:4188: -11.42

Amcad Biomed Return-on-Tangible-Asset Historical Data

The historical data trend for Amcad Biomed's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amcad Biomed Return-on-Tangible-Asset Chart

Amcad Biomed Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only -5.83 -5.97 -4.71 -10.72 -9.95

Amcad Biomed Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -9.11 -11.49 -9.70 -9.88 -14.62

Competitive Comparison of Amcad Biomed's Return-on-Tangible-Asset

For the Medical Devices subindustry, Amcad Biomed's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amcad Biomed's Return-on-Tangible-Asset Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Amcad Biomed's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Amcad Biomed's Return-on-Tangible-Asset falls into.



Amcad Biomed Return-on-Tangible-Asset Calculation

Amcad Biomed's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-45.314/( (472.149+438.967)/ 2 )
=-45.314/455.558
=-9.95 %

Amcad Biomed's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2024 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=-62.556/( (438.967+416.944)/ 2 )
=-62.556/427.9555
=-14.62 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Mar. 2024) net income data.


Amcad Biomed  (ROCO:4188) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Amcad Biomed Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Amcad Biomed's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Amcad Biomed (ROCO:4188) Business Description

Traded in Other Exchanges
N/A
Address
No. 167, Fuxing North Road, 5th Floor, Zhongshan District, Taipei, TWN, 104
Amcad Biomed Corp develops computer-aided detection and diagnosis(CADe/CADx) software devices. Its product pipeline includes AmCAD-UT Detection, a software solution for thyroid nodules analysis; AmCAD-UV, a software device that is used for quantifying and classifying the ultrasonic color intensity data acquired from FDA-cleared ultrasound systems and displaying the noise-reduced color-coded pulsatile signals; AmCAD- U.S, a software device for viewing and quantifying ultrasound image data of backscattered signals; and AmCAD-UO offers detection for obstructive sleep apnea on awake patients to identify the root cause of sleep apnea. The company's geographical segments include Taiwan, China, and other countries, out of which the majority of the revenue is generated from China.

Amcad Biomed (ROCO:4188) Headlines

No Headlines